Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.58 |
| ▸ | HTR6 | P50406 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL682816 | 0.92 | TSHR (0.55) | HTR7HTR6TSHRL3MBTL1ADORA2B | |
| SCHEMBL2626922 | 0.91 | HTR7 (0.63) | HTR7HTR6TSHRL3MBTL1ADORA2B | |
| SCHEMBL684356 | 0.89 | HTR7 (0.58) | HTR7HTR6TSHRL3MBTL1ADORA2B | |
| SCHEMBL682814 | 0.88 | HTR7 (0.56) | HTR7HTR6TSHRL3MBTL1ADORA2B | |
| SCHEMBL684024 | 0.87 | HTR7 (0.51) | HTR7HTR6TSHRL3MBTL1ADORA2B | |
| SCHEMBL683660 | 0.87 | HTR7 (0.51) | HTR7HTR6TSHRL3MBTL1ADORA2B | |
| SCHEMBL682820 | 0.86 | L3MBTL1 (0.73) | HTR7HTR6TSHRL3MBTL1 | |
| SCHEMBL684037 | 0.85 | LMNA (0.54) | HTR7HTR6TSHRL3MBTL1ADORA2B | |
| SCHEMBL683655 | 0.85 | HTR7 (0.77) | HTR7HTR6TSHRL3MBTL1ADORA2B | |
| SCHEMBL11150077 | 0.83 | HTR7 (0.58) | HTR7HTR6TSHRL3MBTL1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | HTR7 1398/4885HTR6 683/4885TSHR 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.